Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

113 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Eliglustat compared with imiglucerase in patients with Gaucher's disease type 1 stabilised on enzyme replacement therapy: a phase 3, randomised, open-label, non-inferiority trial.
Cox TM, Drelichman G, Cravo R, Balwani M, Burrow TA, Martins AM, Lukina E, Rosenbloom B, Ross L, Angell J, Puga AC. Cox TM, et al. Among authors: angell j. Lancet. 2015 Jun 13;385(9985):2355-62. doi: 10.1016/S0140-6736(14)61841-9. Epub 2015 Mar 26. Lancet. 2015. PMID: 25819691 Clinical Trial.
Effect of oral eliglustat on splenomegaly in patients with Gaucher disease type 1: the ENGAGE randomized clinical trial.
Mistry PK, Lukina E, Ben Turkia H, Amato D, Baris H, Dasouki M, Ghosn M, Mehta A, Packman S, Pastores G, Petakov M, Assouline S, Balwani M, Danda S, Hadjiev E, Ortega A, Shankar S, Solano MH, Ross L, Angell J, Peterschmitt MJ. Mistry PK, et al. Among authors: angell j. JAMA. 2015 Feb 17;313(7):695-706. doi: 10.1001/jama.2015.459. JAMA. 2015. PMID: 25688781 Free PMC article. Clinical Trial.
Improvement of bone disease by imiglucerase (Cerezyme) therapy in patients with skeletal manifestations of type 1 Gaucher disease: results of a 48-month longitudinal cohort study.
Sims KB, Pastores GM, Weinreb NJ, Barranger J, Rosenbloom BE, Packman S, Kaplan P, Mankin H, Xavier R, Angell J, Fitzpatrick MA, Rosenthal D. Sims KB, et al. Among authors: angell j. Clin Genet. 2008 May;73(5):430-40. doi: 10.1111/j.1399-0004.2008.00978.x. Epub 2008 Feb 27. Clin Genet. 2008. PMID: 18312448 Free PMC article.
Clinical response to eliglustat in treatment-naïve patients with Gaucher disease type 1: Post-hoc comparison to imiglucerase-treated patients enrolled in the International Collaborative Gaucher Group Gaucher Registry.
Ibrahim J, Underhill LH, Taylor JS, Angell J, Peterschmitt MJ. Ibrahim J, et al. Among authors: angell j. Mol Genet Metab Rep. 2016 Jun 27;8:17-9. doi: 10.1016/j.ymgmr.2016.06.003. eCollection 2016 Sep. Mol Genet Metab Rep. 2016. PMID: 27408819 Free PMC article.
Longitudinal changes in bone density in hyperparathyroidism.
Fuliehan GE, Moore F Jr, LeBoff MS, Hurwitz S, Gundberg CM, Angell J, Scott J. Fuliehan GE, et al. Among authors: angell j. J Clin Densitom. 1999 Summer;2(2):153-62. doi: 10.1385/jcd:2:2:153. J Clin Densitom. 1999. PMID: 10499974
113 results